EUVIMEDEUVIMED entdecken
FallberichtLeitlinieOpen Access

Complimentary Episignature Testing for Variant Reclassification: Case Reports with Variant Classification Guideline Consideration

Pratibha Bawa, Jessica Rzasa, Jennifer Kerkhof, Michael A Levy, Bekim Sadikovic, Shifali Gupta, Rajni Sharma, Priyanka Srivastava, Inusha Panigrahi, Anupriya Kaur

Molecular Syndromology · 21.05.2026 · 1-9

DOI: 10.1159/000552586 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Syndromology, online erschienen am 21.05.2026. Verfasst von Pratibha Bawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Variants of uncertain significance (VUS) are being increasingly encountered in contemporary clinical genetics practice. Peripheral blood derived global DNA methylation pattern or Episignatures have been established for several Mendelian disorders. Case Presentation: We describe in detail the phenotype, genotype and episignature analysis of two children with atypical presentations of Rubinstein-Taybi and Cornelia de Lange syndromes. Whole exome sequencing showed missense VUS (CREBBP:c.3503A>G p.(Asn1168Ser) and NIPBL:c.6535T>G p.(Tyr2179Asp). Infinium Human Methylation 935 (EPICv2 array) was performed followed by methylation analysis using the EpiSign™ METRIC (Methylation based Episignature Testing and Reference based Interpretation and Classification) V5 assay. METRIC score of 1 suggesting high confidence concordance with the episignature pattern associated with pathogenic variants in CREBBP and NIPBL was obtained.

Conclusion

We introduce the METRIC scoring component of the EpiSign™ assay, which provides an integrated assessment of concordance between a patient’s methylation profile and established episignatures, representing an evolution from earlier approaches using Methylation Variant Probability (MVP) scoring. While formal guidance for Bayesian point-based use of episignature results is not yet established, this functional evidence has clear potential for future incorporation and may enhance variant interpretation when combined with genomic data.

Schlagwörter

Stichwörter der Autor:innen

ChromatinopathyEpiSign™ METRIC V5 AssayEpisignatureGlobal DNA methylation

Autor:innen und Institutionen

  • Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Verspeeten Clinical Genome Centre, London Health Science Centre, London, ON, Canada.
  • Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada.

Zitieren

APA

Bawa, P., Rzasa, J., Kerkhof, J., Levy, M. A., Sadikovic, B., Gupta, S., Sharma, R., Srivastava, P., Panigrahi, I., & Kaur, A. (2026). Complimentary Episignature Testing for Variant Reclassification: Case Reports with Variant Classification Guideline Consideration. Molecular Syndromology, 1-9. https://doi.org/10.1159/000552586

Vancouver

Bawa P, Rzasa J, Kerkhof J, Levy MA, Sadikovic B, Gupta S, et al. Complimentary Episignature Testing for Variant Reclassification: Case Reports with Variant Classification Guideline Consideration. Molecular Syndromology. 2026:1-9. doi:10.1159/000552586

BibTeX
@article{Bawa2026,
  author = {Bawa, Pratibha and Rzasa, Jessica and Kerkhof, Jennifer and Levy, Michael A and Sadikovic, Bekim and Gupta, Shifali and Sharma, Rajni and Srivastava, Priyanka and Panigrahi, Inusha and Kaur, Anupriya},
  title = {Complimentary Episignature Testing for Variant Reclassification: Case Reports with Variant Classification Guideline Consideration},
  journal = {Molecular Syndromology},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000552586}
}
Kostenlos starten →